Analyst Price Targets — RBOT
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| November 13, 2024 3:19 pm | Adam Maeder | Piper Sandler | $10.50 | $6.07 | StreetInsider | Vicarious Surgical inc. (RBOT) PT Lowered to $10.50 at Piper Sandler |
| July 18, 2022 10:07 am | — | BTIG | $7.00 | $3.50 | Benzinga | BTIG Maintains Buy on Vicarious Surgical, Lowers Price Target to $7 |
| May 10, 2022 6:29 am | — | Piper Sandler | $5.00 | $3.56 | Benzinga | Piper Sandler Maintains Neutral on Vicarious Surgical, Lowers Price Target to $5 |
Latest News for RBOT
WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (OTCID: RBOT), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Financial Results Total operating expenses were $9.3 million in the fourth quarter of…
WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical Inc. (NYSE: RBOT) (the “Company”), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced that on March 3, 2026, it received a notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) that the NYSE has commenced the process of delisting the Company's Class A common stock, par value $0.0001…
NEW YORK--(BUSINESS WIRE)--The New York Stock Exchange (“NYSE”, the “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the Class A common stock of Vicarious Surgical Inc. (the “Company”) — ticker symbol RBOT — from the NYSE. Trading in the Company's Class A common stock will be suspended immediately. NYSE Regulation reached its decision to delist the…
WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical (NYSE: RBOT) (the “Company”), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced the successful completion of an in-vivo porcine lab conducted in December 2025, marking a meaningful step forward in the development of the company's robotic system and reinforcing progress toward system design freeze…
Vicarious Surgical inks a software execution partnership to streamline development, cut costs and improve predictability.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for RBOT.
U.S. House Trading
No House trades found for RBOT.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.